Valente Federica, Stefanidis Constantin, Vachiéry Jean-Luc, Dewachter Céline, Engelman Edgard, Vanden Eynden Frédéric, Roussoulières Ana
Department of Cardiology, Erasme University Hospital, Université Libre de Bruxelles, 808 Route de Lennik, 1070, Brussels, Belgium.
Department of Cardiac Surgery, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
J Artif Organs. 2023 Mar;26(1):24-35. doi: 10.1007/s10047-022-01334-3. Epub 2022 Apr 28.
Right Heart Failure (RHF) is a severe complication that can occur after left ventricular assist device (LVAD) implantation, increasing early and late mortality. Although numerous RHF predictive scores have been developed, limited data exist on the external validation of these models. We therefore aimed at comparing existent risk score models and identifying predictors of severe RHF at our center.
In this retrospective, single-center analysis, clinical, biological and functional data were collected in patients implanted with a LVAD between 2011 and 2020. Early severe RHF was defined as the use of inotropes for ≥ 14 days, nitric oxide use for ≥ 48 h or unplanned right-sided circulatory support. Risk models were evaluated for the primary outcome of RHF or RVAD implantation by means of logistic regression and receiver operating characteristic curves.
Among 92 patients implanted, 24 (26%) developed early severe RHF. The EUROMACS-RHF risk score performed the best in predicting RHF (C = 0.82-95% CI: 0.68-0.90), compared with the other scores (Michigan, CRITT). In addition, we developed a new model, based on four variables selected for the best reduced logistic model: the INTERMACS level, the number of inotropes used, the ratio of right atrial/pulmonary capillary wedge pressure and the ratio of right ventricle/left ventricle diameters by echocardiography. This model demonstrated significant discrimination of RHF (C = 0.9-95% CI: 0.76-0.96).
Amongst available risk scores, EUROMACS-RHF performs best to predict the occurrence of RHF after LVAD implantation. Our model's performance compares well to the EUROMACS-RHF score, adding a more objective parameter to RV function evaluation.
右心衰竭(RHF)是左心室辅助装置(LVAD)植入术后可能发生的严重并发症,会增加早期和晚期死亡率。尽管已经开发了许多RHF预测评分,但关于这些模型的外部验证的数据有限。因此,我们旨在比较现有的风险评分模型,并确定我们中心严重RHF的预测因素。
在这项回顾性单中心分析中,收集了2011年至2020年间植入LVAD的患者的临床、生物学和功能数据。早期严重RHF定义为使用血管活性药物≥14天、使用一氧化氮≥48小时或无计划的右侧循环支持。通过逻辑回归和受试者工作特征曲线评估风险模型对RHF或RVAD植入这一主要结局的预测情况。
在92例植入患者中,24例(26%)发生了早期严重RHF。与其他评分(密歇根评分、CRITT评分)相比,EUROMACS - RHF风险评分在预测RHF方面表现最佳(C = 0.82 - 95% CI:0.68 - 0.90)。此外,我们基于为最佳简化逻辑模型选择的四个变量开发了一个新模型:INTERMACS级别、使用的血管活性药物数量、右心房/肺毛细血管楔压比值以及超声心动图测量的右心室/左心室直径比值。该模型对RHF具有显著的鉴别能力(C = 0.9 - 95% CI:0.76 - 0.96)。
在可用的风险评分中,EUROMACS - RHF在预测LVAD植入术后RHF的发生方面表现最佳。我们模型的性能与EUROMACS - RHF评分相当,为右心室功能评估增加了一个更客观的参数。